Location: Exotic & Emerging Avian Viral Diseases ResearchTitle: Biosafety risk assessment for production of candidate vaccine viruses to protect humans from zoonotic highly pathogenic avian influenza viruses
|CHEN, LI-MEI - Centers For Disease Control And Prevention (CDC) - United States|
|DONIS, RUBEN - Centers For Disease Control And Prevention (CDC) - United States|
|WENTWORTH, DAVID - Centers For Disease Control And Prevention (CDC) - United States|
|WEBBY, RICHARD - St Jude Children’s Research Hospital|
|ENGELHARDT, OTHMAR - The National Institute For Biologial Standards And Control|
Submitted to: Influenza and Other Respiratory Viruses
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 10/8/2019
Publication Date: 2/5/2020
Publication URL: https://handle.nal.usda.gov/10113/6964474
Citation: Chen, L., Donis, R.O., Suarez, D.L., Wentworth, D.E., Webby, R., Engelhardt, O.G., Swayne, D.E. 2019. Biosafety risk assessment for production of candidate vaccine viruses to protect humans from zoonotic highly pathogenic avian influenza viruses. Influenza and Other Respiratory Viruses. 14:215-225. https://doi.org/10.1111/irv.12698.
Interpretive Summary: A shortened time period is needed for delivery of vaccines to prepare for an influenza pandemic. One critical need was an accelerated process to approve candidate vaccine viruses (CVV) for use in vaccine manufacture. In this study, we provided 15 years of biosafety evidence in support of eliminating mandatory chicken safety testing requirements, thus expediting the transfer of vaccine candidates to manufacturing by nearly three weeks.
Technical Abstract: A major lesson learned from the public health response to the 2009 H1N1 pandemic was the need to shorten the vaccine delivery timeline to achieve the best pandemic mitigation results. A gap analysis of previous pre-pandemic vaccine development activities identified possible changes in the Select Agent exclusion process that would maintain safety and shorten the timeline to develop candidate vaccine viruses (CVVs) for use in pandemic vaccine manufacture. Here, we review the biosafety characteristics of CVVs developed in the past 15 years to support a shortened preparedness timeline for A(H5) and A(H7) subtype highly pathogenic avian influenza (HPAI) CVVs. Extensive biosafety experimental evidence supported recent changes in the implementation of Select Agent regulations that eliminated the mandatory chicken pathotype testing requirements and expedited distribution of CVVs to shorten pre-pandemic and pandemic vaccine manufacturing by up to 3 weeks.